[
  {
    "ts": null,
    "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "summary": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743155082,
      "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
      "id": 133508460,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75"
    }
  },
  {
    "ts": null,
    "headline": "Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials",
    "summary": "Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I rate CRVS stock as a Hold.",
    "url": "https://finnhub.io/api/news?id=74d837da9fa83c9b38f66e46281ecc5bbc772637cb121e0f5b2521cffd46ea9a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743154200,
      "headline": "Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials",
      "id": 133508412,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370321402/image_1370321402.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I rate CRVS stock as a Hold.",
      "url": "https://finnhub.io/api/news?id=74d837da9fa83c9b38f66e46281ecc5bbc772637cb121e0f5b2521cffd46ea9a"
    }
  },
  {
    "ts": null,
    "headline": "Corvus Pharmaceuticals: Now At Cruising Altitude",
    "summary": "Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in...",
    "url": "https://finnhub.io/api/news?id=1b08225a60a8aeaa240ed02edad15db849102f3d8fd8ba0c97862add3f29bdf2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743154195,
      "headline": "Corvus Pharmaceuticals: Now At Cruising Altitude",
      "id": 133508413,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1148535002/image_1148535002.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in...",
      "url": "https://finnhub.io/api/news?id=1b08225a60a8aeaa240ed02edad15db849102f3d8fd8ba0c97862add3f29bdf2"
    }
  },
  {
    "ts": null,
    "headline": "RNA Biotechs: Current State And Outlook",
    "summary": "RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=1f3638fe5d94396e4de4d10d757d411c0123cc3cebc9f3478bbed086637c300b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743152439,
      "headline": "RNA Biotechs: Current State And Outlook",
      "id": 133508214,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355122387/image_1355122387.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=1f3638fe5d94396e4de4d10d757d411c0123cc3cebc9f3478bbed086637c300b"
    }
  },
  {
    "ts": null,
    "headline": "Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication",
    "summary": "Intelliaâs nex-z gets FDA RMAT for ATTR-CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.",
    "url": "https://finnhub.io/api/news?id=fd3d0a821709e20b4ebf69357265a026042c69cce7110a42e2635aee9e80c498",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743143052,
      "headline": "Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication",
      "id": 133506913,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192921796/image_2192921796.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Intelliaâs nex-z gets FDA RMAT for ATTR-CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.",
      "url": "https://finnhub.io/api/news?id=fd3d0a821709e20b4ebf69357265a026042c69cce7110a42e2635aee9e80c498"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)",
    "summary": "Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation TARRYTOWN, N.Y. and PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and",
    "url": "https://finnhub.io/api/news?id=8775044f250d9a4cef6fa2453c01e9141e70e5849b69d258147659055385f929",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743141600,
      "headline": "Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)",
      "id": 133505739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation TARRYTOWN, N.Y. and PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and",
      "url": "https://finnhub.io/api/news?id=8775044f250d9a4cef6fa2453c01e9141e70e5849b69d258147659055385f929"
    }
  }
]